For the shareholders that cant attend these meetingsMiniutes Of...

For the shareholders that cant attend these meetings

Miniutes Of Meeting

More news flow in the coming weeks
Robert Clarke; Instimental in his DD on the company and an intregal part of fast tracking regletory and FDA obligations
Overseeing and working towards T/O and acquisitions but with an overall bussiness plan aiming at commercialisation and marketing.
28 assets developed in house
All with a distinct focus on reglatory obligations, commercialisation and marketing our assets
Hiring Heat of Corporate Development officer to oversee and concentrate on quick commercialisation of each assets

IHL42X
Approval from FDA massive acheivement in this short time via RC expertise.
47 sites 400-600 patients
Accessable market of $10bn
Trials to start in November once final reglatory obligations met
52 week trial with interum updates to the market at 3, 6 and 12 months
Restmed showing interest and IHL42X could be acquired before product design and marketing but still focused on the bussiness model to bring all assets to the market.
Restmed efficency on CPAP 46% IHL42X just under 60% 25% patients at 82% and 1 at 90%
No linguring side effects

PSI GAD
All applications nearing completion
Commited to manufacture and product design
FDA 4th qtr

IHL675A
Current phase 2 120 patients
Updates and interums 4 qtr

Gum
CanQuite N 5.2bn market
CanQuite O 64bn market
Rennecan Dermatology Massive market
6 EDA/EMA underway
Pre IND by xmas
Product design underway

Clinics
Many patient enquiries
Clinic ready in coming days and aiming at patient intake next month
Multi Bn market in Australia alone
World eyes are watching this space.
World leaders with Dr PL at the helm and highly regarded via Monarch
Cashflow positive very quickly with further clinics to open swiftly

Redomicile
Maximise assets in the US
Liquidity tight under current platform for larger US investors to take positions
Better CR opportunities due to more depth in liquidity
Easier for T/O or acquisitions
Mother company Delware to safeguard any hostile T/O or Acquisitions.
US share registry have been commissioned for the transition
Australian investorrs will be notified once redomiciled/transfer and a start up trading platform can be opened for trading direct through the US registry or choose their own broker.
Joel is activily finalising for SMSF to transfer into US entity
Hugh CR platform for Joel in the coming months with US interest.
R and D to stay in Australia. Government funded R and D programs to 47% expenditure.
Voting to be held some time in late October with swift Transfer within a week after shareholder approval
Aiming at early Novermber Transfer after a 2 week Traded Hault for US NASDAQ commission and to give shareholders time to set up their trading plateforms.

Joel and team were awesome.
Well articulated presentation, open to all questions, precise with a solid game plan to gain traction in the share price and move our assets into commercialisation.
The underlying factor underpinning our assets is the hugh potential for a T/O or Acquisition. Placing IHL amoungst its peers with market Caps at multipules of where IHL is and with far less assets, market access and portfolio diversification.
I had a good 1hr+ chat with Joel and his dedication drive and passion for IHL and their shareholders is increadable. Yes we will have some pain in the SP during this redomicile period but come November its all systems go. The critisism about Joel on HC is totally unfounded and one needs to look at fundamentals, what the company is doing and acheiving behind the scenes and the wealth of expertise the team have all experts in their feild and second to non. IHL are truely world class and ahead of their compeditors.
GLAH